Pfizer completes pneumonia case accrual for CAPiTA
CAPiTA's mission was to determine if Prevenar 13 could be effective in preventing community-acquired pneumonia caused by the 13 pneumococcal serotypes that are included in the vaccine. The event drive clinical study, which was the largest trial of its kind, used a pre-specified number of community-acquired, vaccine-type pneumococcal pneumonia cases.
The processing of the case by Julius Clinical is not yet complete and will take several months to finish.
Prevenar 13 is used in more than 120 countries worldwide, which makes it one of the most widely used pneumococcal conjugate vaccines in the world. It was first approved for infants and young children in Europe in 2009. It has since been approved in various countries for patients over the age of 50.
Pfizer is a pharmaceutical company that uses science and global resources to bring new therapies to people around the world. Pfizer was founded more than 150 years ago and collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care.